Anyone having lectured on DNA adducts is likely to be familiar with the first question after the presentation: 'What is the relationship of DNA adducts and cancer?'. Although there are a number of reviews on the topic (1-5), my personal response, instead of going into lengthy circumstantial argumentation and hand-waving, has been a quotation from Mortimer Mendelson: 'I wouldn't like to have my DNA messed up'. In this commentary I will indulge in this still circumstantial argumentation. The reason being that never before has it appeared to be so easy, or less difficult, to entertain the question. Hopefully this effort will spare colleagues confronting the same question some time. At the same time I will take the opportunity to describe developments in the identification of DNA adducts. A vivid history of the development of ideas on chemical causes of cancer has been published by Lawley (2).
Adducts in humans
The development of sensitive methods based on ^P-postlabelling (9-11) and immunoassay (12) has laid the groundwork for determination of DNA adducts in humans. Gas chromato- Table I graphic-mass spectrometric techniques have been used to determine protein adducts (3) . These techniques are new, everimproving and expanding (13) , and due caution must be exercised concerning the accuracy of such measurements. Inter-laboratory comparisons carried out on the postlabelling technique, immunoassays or both have shown reasonable correlations (14 -16), but unknown variables exist and there is no proof that in human DNA the two assays measure identical adducts.
One of the problems in measuring DNA adducts is specificity, i.e. detection of a particular type of adduct using stringent structural criteria. This has been achieved for only a few human DNA adducts (Table IT) . The data are compiled from references (17) (18) (19) (20) (21) . In the postlabelling method, such specificity has apparently been achieved in humans for 7-methylguanine (22, 23) ,O 6 -methylguanine (24) and benzo[a]pyrene-DNA adducts (16, 25) . It is not yet clear how specific immunoassays are without prepurification of the adducts. Immunoassay of cisplatin adducts after high-performance liquid chromatography is a likely method for detecting specific adducts (26) . Antibodies to DNA adducts are useful for prepurifying adducts by affinity column chromatography and will probably facilitate the identification of specific adducts. A competitive DNA repair assay has been used to measure C^-methylguanine in human DNA (27) .
Although quantitation of the adducts in diese studies may be somewhat uncertain, internal or external standards are useful, if not mandatory, for accurate results. Interestingly, two studies using standards gave almost identical quantifications of lung and lymphocyte 7-methylguanine levels (28) (29) (30) .
DNA adducts and mutations
Many known mutagens form covalent DNA adducts (6, 7, 31) that are released from DNA either spontaneously or by biological repair processes. Ample evidence suggests that mutations arise either during DNA replication at the damaged site or during errorprone DNA repair (32) .
The use of shuttle vectors with built-in specific adducts has provided the ultimate piece of evidence for the promutagenic role of adducts in mammalian cells. Mutations induced by a large number of compounds, from small alkylating agents to arylating agents, and irradiation have been scored and characterized using shutde vectors (33) (34) (35) . Up to the present, dozens of specific adducts have been tested in such systems. Interesting aspects of these studies are the sequence specificity of adduct formation and of subsequent mutations (mutational hot spots) and the mutational efficiency of different adducts, from barely mutagenic to those that frequently cause mutations. The data obtained to date provide unequivocal evidence that many, if not most, adducts have the potential to cause mutations.
An example of the mutational specificity of five chemical agents, UV light and spontaneous mutations on exon 3 of the hypoxanthine phosphoribosyltransferase (HPRT) gene is shown in Figure 1 (generously provided by Alexandra Kat and William Thilly; 36).
One aspect worth pointing out is that the mutations usually occur at bases that are known targets for the agents, e.g. guanine for MNNG, BPDE; guanine and adenine for cisplatin; adenine for hydrogen peroxide (36) . Another notable feature is the sitespecificity. Even with the limited number of mutants scored, the site-specificity is striking, but unexplained.
The mutations induced by UV light are particularly interesting. The predominant, but not the only, UV-induced adducts are cyclobutane or 6,4-photoproducts at dipyrimidine sites. In exon 3 of HPRTthymine bases are hot spots, but mutations also occur at guanines. However, in several other studies, including the HPRT gene, it has been shown that UV light induces typical tandem double mutations at dipyrimidine sites (36) . This is important for later discussion.
The other well characterized genes, adenine phosphoribosyl transferase and dihydrofolate reductase, also demonstrate mutations at nucleotides that are known targets of the mutagen used (4, 37) . Mutations induced chemically in the ras oncogene family also usually follow the known base-specificity of the mutagen used (4, 37) .
DNA repair of adducts depends on a number of factors, including the type of adduct. In the dihydrofolate reductase (DHFR) and HPRT genes of many types of cultured cells it has been demonstrated that for certain adducts removal is faster in the gene than in the non-coding region close to the gene, or faster in the transcribed as compared to the non-transcribed strand (38) . Both preferential repair of the active region and of the transcribed strand have been described for UV-, nitrogen mustard-and cisplatin-induced adducts. By contrast, neither type of preference was seen with dimethyl sulphate or 4-nitroquinoline 1-oxide. Preferential repair of adducts in the transcribed strand poses the question of fixation of mutations. In genes such as HPRT and DHFR in many types of cultured cells it has been demonstrated that many mutagens cause mutation primarily in die non-transcribed strand (33) . Strand-bias is also seen in tumours. In mice irradiated by UV light all the dipyrimidine mutations were on die non-transcribed strand (39) Extensive work carried out on p53 tumour suppressor gene mutations has shed light on the origin of 'spontaneous mutations'.
Among
have a mutation at Q. As CG is the recognition site for cytosine methylase, it is assumed that the mutagenic lesion is deamination of 5-methylcytosine to thymine. Such a lesion would appear spontaneous, but why it should be particularly prevalent in colon cancer and practically non-existent in many other cancer sites remains unexplained (40) .
Other mechanisms of spontaneous mutation may involve insertions and deletions. An analysis of deletions in thep53 gene revealed a copy of the deleted sequence in close vicinity to die deleted one. The insertions were usually duplications of an existing sequence (41) . The mechanism of both types of mutations may be slipped mispairing in DNA synthesis.
Additionally, it is known that a number of endogenous DNAbinding or -damaging chemicals exist. S-Adenosylmethionine is capable of methylating DNA. Hydroxyradicals can damage DNA. Depurination and deamination are reactions proceeding at a constant background rate and are likely to contribute to spontaneous mutations.
DNA adducts and cancer
DNA adduct levels have been studied in animal models in target and non-target tissues in relation to known tumour responses. This work has led to some understanding of the role of DNA adducts. Firstly, adducts, if detectable at all, are usually found in target and non-target tissues, indicating that adducts are not the only reason for tissue specificity (1,3). It is not unexpected that lipophilic, directly reactive carcinogens, such as ethylene oxide, alky late DNA in many tissues to a roughly equal extent (42, 43) . Secondly, in target tissues of a particular class of carcinogens, DNA-binding may be correlated with carcinogenic potency (1,44). Unfortunately, N-nitroso compounds, on which a large amount of literature is available, have not been analysed quantitatively for such correlations (45) . Thirdly, DNA binding to tissue DNA appears to be linear over a wide dose range for many compounds, irrespective of whether tumours are formed in the tissue (3, 46) . Fourthly, carcinogens that react with specific sites in DNA appear to have different efficacies in causing tumours: Oalkylation appears to be effective for small alkylating agents (3, 13) , while many potent, large carcinogens react with the A^-position of guanine (47) . Fifthly, the stability of adducts in DNA appears to be related to die probability that tumours will occur (48) (49) (50) . Sixthly, in some, but not all, cases the target organs of sensitive animal species have higher levels of DNA adducts than the same organs in resistant species (51).
These observations show diat there is no simple algoridim for translating DNA adduct levels into cancer risk in a particular tissue. While some of the paradoxes may only be apparent and explicable technically, the biological complexity of cancer may be such that simple algorithms never hold. The adducts of only five compounds have been measured in chronic carcinogenicity studies, as part of a bioassay or in long term simulation experiments (52) . These studies include liver and bladder adducts of 2-acetylaminofluorene and 4-aminobiphenyl, liver adducts of aflatoxin Bl and diethylnitrosamine and lung adducts of a tobaccospecific nkrosamine, 4-(A r -mediyl-A^-nitrosoamino)-l-(3-pyridyl)-1-butanone. In all cases the adduct levels were linear at low doses. For most of the compounds, adduct levels correlated with tumour yields. Poirier and Beland conclude: 'Taken together, these data suggest that when extrapolating from higher doses to low doses within an animal model, the extent of DNA adduct formation will most often correlate widi the extent of tumorigenesis.
However, in animal model experiments where the number of animals is limited, tumour incidences may not be measurable when DNA adduct levels are low or in the absence of toxicity and/or cell proliferation' (53) .
In the case of 4-aminobiphenyl, adducts have been measured in urinary bladder DNA both in experimental animals and in humans. Poirier and Beland (53) calculated that the 50% tumour incidence equalled 156 frnol adducts//ig DNA in mice as compared to 0.815 fmol//ig in humans. The levels refer to the main 4-aminobiphenyl adduct at the C8 position of guanine. A correction for life-span still showed that higher levels of adducts were required in mouse than man to induce tumours. Although such calculations rely on a number of assumptions (52), they show that new technologies allow such comparisons. The conclusion from 4-aminobiphenyl was that, per unit dose, humans appeared to be more sensitive than mice for the induction of bladder tumours.
Mutations and cancer
The mutational theory of cancer is old, but the best evidence in support of it has emerged relatively recently. The chromosomal instability syndromes, which are linked to increased risks of cancer, provided some early evidence; similarly, the demonstration of specific chromosomal changes in certain malignancies implied the occurrence of mutational events. More recently, molecular mapping of chromosomal changes, such as the translocation between chromosomes 22 and 9 in chronic myeloid leukaemia (Philadelphia chromosome) showed that important growth controlling genes, including some oncogenes, are located in the translocated DNA (53) . Molecular characterization of retinoblastoma demonstrated the presence of another class of growth controlling genes, anti-oncogenes (54) (55) (56) . Functional incapacitation of the two alleles of the retinoblastoma gene confers malignancy. Whether exogenous or endogenous chemicals or aberrations of normal cellular functions, or all of these, underlie these events remains to be established. The common types of activation of oncogenes include point mutations, translocations and amplifications, whereas point mutations and deletions appear to be mechanisms for inactivating tumour suppressor genes (56) (57) (58) . Recently a type of genetic instability was described in familial colorectal cancer (59) (60) (61) . This disease, mapped to chromosome 2, is characterized by the insertion of di-and trinucleotide repeats in several chromosomal locations.
Point mutations have been shown to be important in activation of the ras and neu oncogenes; ras is found in many types of human cancers and neu particularly in breast cancer (57) . Mutations of ras and neu have been induced in rodents by Nnitroso compounds, vinyl chloride, aflatoxin Bl, tetranitromethane, polycyclic aromatic hydrocarbons, benzidine derivatives, urethane and ionizing radiation (4) . Mutations of ras are commonly detected in human cancers, particularly of the pancreas, lung and colon (58) . There are, however, a few clues to the origin of these mutations.
The strongest evidence linking adducts, mutations and cancer comes from the p53 gene, where specific mutations appear to be present in liver cancers of populations assumed to ingest large quantities of aflatoxin Bl (4, 40) .
The case with UV adducts and skin cancer appears even stronger. As pointed out earlier, UV light is known to induce rare tandem dipyrimidine mutations in eukaryotic systems. These are not unique to UV light, but are usually infrequent with agents such as aflatoxin Bl (62) and oxygen radicals (63) . In UV-Birradiated mouse skin 35 epidermal tumours were analysed for point mutations in the p53 gene. Of the seven mutations, all occurred at tandem dipyrimidines, and two were tandem dipyrimidine, CC to TT mutations (39) .
According to one paper, of 24 human squamous cell carcinomas analysed 14 had p53 mutations, most involving dipyrimidine sites, three tumours involving a CC-TT dipyrimidine change (64) . In a recent study essentially similar results were obtained with basal cell carcinomas (65) . In cloned p53 DNA, after UV irradiation, dipyrimidine photoproducts were detected in mutational hot spots and some other sites, indicating that factors in addition to the photoproducts influence the frequency of mutations (65) . In two other studies on squamous cell carcinomas lower frequencies of p53 mutations were noted, but dipyrimidine sites were overwhelming in basal cell carcinomas also (66) . Moreover, p53 tandem dipyrimidine mutations have also been detected in some cells of normal sun-exposed skin areas (67) .
Conclusions
Cancer research has experienced a revolution during the past decade. The emphasis has been on the characterization of new genes and their functions. After completion of the human genome map the emphasis will be on function and regulation. The complex, intricate functional networks make the charts of metabolic pathways of the 1970s look like single pages of a map book.
Arguments about whether chemicals or genes, environment or genetic constitution cause cancer seem obsolete. We have learned that chemicals cause cancer through genetic changes. Furthermore there are genetic changes involved in carcinogenesis that appear spontaneous, or at least endogenous. The mystery of how DNA adducts relate to genetic changes is under intensive study. Why only certain mutations manifest in tumours depend on biological selection and the type of gene affected are areas where we are still apprentices.
What is the relationship between DNA adducts and cancer? It is a chronic messing up of our DNA.
